Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBITDA: 2020-2024

Historic EBITDA for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$115.4 million.

  • Tarsus Pharmaceuticals' EBITDA rose 46.13% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 39.39%. This contributed to the annual value of -$115.4 million for FY2024, which is 15.06% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EBITDA stood at -$115.4 million for FY2024, which was up 15.06% from -$135.8 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year EBITDA high stood at -$13.8 million for FY2021, and its period low was -$135.8 million during FY2023.
  • Over the past 3 years, Tarsus Pharmaceuticals' median EBITDA value was -$115.4 million (recorded in 2024), while the average stood at -$104.5 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' EBITDA skyrocketed by 48.43% in 2021, and later tumbled by 349.59% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBITDA (Yearly) stood at -$26.8 million in 2020, then soared by 48.43% to -$13.8 million in 2021, then slumped by 349.59% to -$62.2 million in 2022, then slumped by 118.48% to -$135.8 million in 2023, then increased by 15.06% to -$115.4 million in 2024.